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Background: Electronic prescribing is now the norm in many countries. We wished to find out if clinical software
systems used by general practitioners in Australia include features (functional capabilities and other characteristics)
that facilitate improved patient safety and care, with a focus on quality use of medicines.
Methods: Seven clinical software systems used in general practice were evaluated. Fifty software features that
were previously rated as likely to have a high impact on safety and/or quality of care in general practice were
tested and are reported here.
Results: The range of results for the implementation of 50 features across the 7 clinical software systems was as
follows: 17-31 features (34-62%) were fully implemented, 9-13 (18-26%) partially implemented, and 9-20 (18-40%)
not implemented. Key findings included: Access to evidence based drug and therapeutic information was limited.
Decision support for prescribing was available but varied markedly between systems. During prescribing there was
potential for medicine mis-selection in some systems, and linking a medicine with its indication was optional. The
definition of ‘current medicines’ versus ‘past medicines’ was not always clear. There were limited resources for
patients, and some medicines lists for patients were suboptimal. Results were provided to the software vendors,
who were keen to improve their systems.
Conclusions: The clinical systems tested lack some of the features expected to support patient safety and quality
of care. Standards and certification for clinical software would ensure that safety features are present and that there
is a minimum level of clinical functionality that clinicians could expect to find in any system.
Background
Electronic prescribing (e-prescribing) offers an opportu-
nity to improve the quality, safety and efficiency of
health care and is now the norm in many countries [1].
There is evidence to show that e-prescribing (often with
clinical decision support) is associated with a reduction
in medication errors and incomplete or unclear orders,
improved drug allergy detection and greater adherence
with clinical practice guidelines [2-4]. There are however
also reports of unintended negative consequences of
e-prescribing, for example unfavourable effects on work-
flow and the introduction of new types of errors [5,6].
Software systems for e-prescribing have been available
for two decades, however standards and certification
processes for these systems have lagged behind develop-
ment and use of the software. Currently there is little
information for funders or users of these systems to
assess how effectively a system supports healthcare
safety and quality.
In Australia, general practitioners (GPs) have been
using clinical software systems that include e-prescribing
for more than 15 years, with rapid uptake encouraged
by government incentives in the 1990s. These systems
have been developed in an unregulated environment,
with little evaluation of their impact on clinical practice
or health outcomes. We wished to find out if current
systems include features that facilitate improved patient
safety and care, with a focus on quality use of medi-
cines. Quality use of medicines is the judicious, effective
and safe use of medicines, and in terms of clinical soft-
ware functionality it encompasses the entire medication
management process.
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ware features (where feature includes functionality or
other characteristic of a software system), with each
feature being rated for its expected impact on safety,
quality and usefulness to the clinician and the patient
[7]. In this study the features were tested in seven clini-
cal software systems. Here we report on the software
testing process and the results for a subset of the
features.
Methods
The study protocol was approved by the Australian
Government Department of Health and Ageing Ethics
Committee.
Features tested
Of the 114 software features previously identified, 104
were tested in software (10 were classified as ‘aspira-
tional’) [7]. In this paper we report on the results for
the 50 features that were rated as likely to have a high
impact on safety and/or quality of care, and that could
be tested in software.
Software systems
Seven commonly used general practice clinical systems
were evaluated: Best Practice™, Genie™, Medical Direc-
tor 2™, Medical Director 3™,M e d T e c h 3 2 ™,P r a c t i x ™
and Profile™. Added together, the users of these sys-
tems account for more than 90% of Australian GPs. All
the systems integrate prescribing within an electronic
health record. For testing, the systems were purchased
and installed on two dedicated laptop computers.
Default settings in the software were not altered unless
the test script specified a change. The software version
tested was the most recent version of the software pro-
duced and available on 1 January 2008.
Development of test scripts
Test scripts were developed using clinical scenarios
based on 11 imaginary patients visiting their GPs. For
each of the features to be tested, one or more test cri-
teria were developed. Each test script was prepared in a
separate Excel worksheet and was designed to produce a
logical flow for testing and to facilitate data entry; there
were 660 executable steps and 350 test criteria in total
for the 104 features. The test scripts were reviewed by a
GP and a health informatician–they provided feedback
on the content, format and clarity of the scripts. An
extract from one of the test scripts is shown in Figure 1.
Software testing
Testing was undertaken independently by two research-
ers in January to April 2008. The same researchers also
carried out pilot testing to assess the usability of the test
scripts and how the process flowed. Full testing fol-
lowed, with the process being completed for each script
across all seven systems prior to starting the next script.
Approximately 2000 screenshots were saved by each
tester.
At the completion of testing for each script, the
results were reviewed and compared between the two
researchers. Where their scores were in agreement, the
test results were accepted. Where there was disagree-
ment, four researchers (ZA, AS, MS, MW) met to dis-
cuss the variation in results and reach a consensus
decision, which in some cases required retesting. At the
end of the test process, one of the researchers (MS)
undertook a line-by-line review of all results to check
the scores and to identify any results that were unclear,
unexpected or inconsistent, and that required verifica-
tion with an expert user or the software vendor.
A number of features could not be tested adequately
within the test environment. A GP expert user of each
system (nominated by the vendor of that system) was
contacted in February 2009 to find out about implemen-
tation of these features in their system. The test scripts
were recast as interview questions that required a yes/
no response. A researcher interviewed each GP at their
practice, requesting a demonstration on the computer
or further details where applicable. The responses were
recorded by hand. Expert users provided information on
the processes for receipt of pathology results and incor-
poration of these results into patient records, use of
messaging, availability of system logs and ease of soft-
ware updates.
Review of preliminary results with software vendors
Test data were collated and the preliminary results were
provided to each software vendor, with a request for
feedback. They were informed that the preliminary
results for their system would be reviewed based on
their feedback, and that the scores would be revised if
there was sufficient evidence to show that the system
included any functionality in question. A face-to-face
meeting or teleconference was held with representatives
from each company in April 2009. Discussion focussed
on features where the test results were unclear or where
there was disagreement. The representatives provided a
demonstration of the system and/or documentation of
functionality to support any claims. Meeting notes were
sent back to each vendor, with further comment invited
by email.
Review of results by study guidance group
Scores were revised based on vendor feedback and these
were provided to the study guidance group for review
and approval. In accepting or rejecting the scores, the
group recommended that: (1) Software features should
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should not ‘pass’ w h e r eaf e a t u r ei sa v a i l a b l eb u tw h i c h
requires extensive configuration or assistance from the
vendor in order to use it; (2) if a feature is dependent
on an external source of information (eg, many of the
decision support features), it should remain as a scored
feature, but with a note that the feature is dependent on
the availability of a suitable knowledge resource; and (3)
for some features the results available were either not
s u f f i c i e n tt os c o r et h ei t e ma ta l l ,o rn o tt os c o r ei t
quantitatively - these were designated ‘not scored’ or
‘description only’. Most of the recommendations were
accepted and scores were increased for all seven sys-
tems, with between 9 and 18% of the scores being
revised across the systems.
Results
The implementation of the 50 scored features in
seven clinical software systems is shown in Figure 2 and
Table 1. Figure 2 provides an aggregate view of the
implementation of the features: of the 50 features, the
number that were fully implemented in the 7 systems
ranged from 17-31 features (34-62%), with 9-13
(18-26%) features being partially implemented, and 9-20
(18-40%) not implemented. Table 1 shows the results
by individual feature. The software systems are not
identified individually as our intention was to look at
features across all systems and make general recommen-
dations for improvement of clinical software.
Important safety features that were included in all or
most systems were alerts for drug-drug interactions,
drugs in pregnancy and allergies. Most systems dis-
played information about allergies and pregnancy and
breastfeeding status throughout the consultation. All
systems had reminders for new pathology results that
were abnormal and for overdue pap smears, and warned
the user when creating or opening a record where there
was another patient with the same name in the system.
There were also some gaps and limitations, as follows:
￿ Variable decision support for prescribing.S o m es y s -
tems provided decision support for therapeutic duplica-
tion (3 systems), drug-condition contraindications (3
systems), drug use in breastfeeding (3 systems) and
renal impairment (2 systems). There was little or no
decision support for harmful dosage regimens or for
safety issues related to specific products, such as recent
warnings issued by the Therapeutic Goods Administra-
tion. Several software vendors cited lack of viable access
to suitable knowledge bases to implement some of these
features.
￿ Limited access to evidence-based drug and therapeutic
information. No system provided access to information
Test Script example – Scenario: Elderly man with multiple medical conditions (extract for one feature)  
Short title  Step 
no. 















3.102  Medications that are the 
same or similar to the 
patient's current medications 
are prescribed to check for 
duplicate therapy alerts. 
                 
   3.103  Prescribe: 
Fosinopril (Monace™)  
10mg tablets (30) 
Dose and frequency:  




Record all alerts/messages 
Warning message - 
Therapeutic duplication 
(patient is already on 
Monoplus™ which contains 
fosinopril). 
Alerts are displayed when a 
selected medication and an 
entry on the medication list are: 
 
Duplicate of same drug (same 
active ingredient) 
DS03  1  1    
   3.104  Cancel prescribing 
Fosinopril 10mg (30) 
                 
   3.105  Prescribe: 
Enalapril (Renitec™)  
5mg tablets (30) 
Dose and frequency:  




Record all alerts/messages 
Warning message - 
Therapeutic duplication 
(already on another drug in 
ACE inhibitor class - 
fosinopril). 
Alerts are displayed when a 
selected medication and an 
entry on the medication list are: 
 
Drugs within same drug class 
eg. ACE inhibitors 
DS03  1  1    
   3.106  Cancel prescribing  
Enalapril 5mg (30) 
                 
   3.107        Total score DS03     2       
   3.108        Maximum score     2       
Figure 1 Extract from a test script.
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the Australian Medicines Handbook and Therapeutic
Guidelines. These resources provide independent, evi-
dence based drug information but at present they are
not available in a format that can readily be incorpo-
rated into clinical software systems. In relation to drug
dosage, all systems provided adult and child dosing
information that was based on the Australian regulator-
approved product information, however this information
source has limitations as it does not include off-label
indications and often does not include paediatric dosage.
￿ Potential for medicine mis-selection at the time of
prescribing. The display of medicines in most systems
was not optimal–long lists of products were displayed in
small windows that required extensive scrolling, and the
same or similarly named products were listed together
with no clear differentiation between them. Only one sys-
tem implemented a method to reduce the risk of mis-
selection by making product selection a two-step process.
￿ Linking a medicine with its indication was optional.
Linking was possible in all systems but in no case man-
datory. Linking is important so that other health provi-
ders know what the medicine is for when health
information is communicated or shared, and for quality
improvement activities eg, comparison of own prescrib-
ing versus best practice guidelines.
￿ Definition of ‘current medicines’ vs ‘past medicines’
was not always clear. Some systems moved a medicine
from the ‘current’ to the ‘past’ list automatically after a
certain period. This is a crucial component of a health
record and there is no standard definition of ‘current
medicines’ and how they should be handled in an elec-
tronic health record.
￿ Medicines lists for patients were suboptimal. All sys-
tems produced a patient version of the current medi-
cines list but in most cases it was suboptimal, being
poorly formatted, omitting the purpose of the medicine,
or using Latin or non-standard abbreviations.
￿ Some systems did not have warnings for allergy cross-
sensitivities. Three systems did not provide an alert
when a cephalosporin was prescribed in a penicillin-
allergic patient.
￿ No standard way to record preventive care and non-
pharmacological management.T h i si sa ni n c r e a s i n g l y
important aspect of care; details were able to be
recorded in different parts of the record or not at all.
￿ Limited patient resources. All systems provided
access to Australian consumer medicines information
leaflets. Availability of other patient resources was vari-
able, ranging from none at all to two systems with a
large number of resources, including leaflets on specific
medicines, health conditions and nutrition.
￿ Variable clinical reporting. The type and number of
predefined clinical reports varied between systems. All
systems enabled user-defined reports to be produced;
however, the flexibility, sophistication and ease of use
Figure 2 Implementation of 50 features expected to have a high positive impact on quality and safety in 7 clinical software systems.
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Page 4 of 8Table 1 Implementation of 50 features* in 7 prescribing systems
Feature Clinical software system
1234567
Patient data
1 Create patient management plans ●●●●●●●
2 Record and display allergies and drug intolerance ●●●●●●◖
3 Record and display clinical information ●●●●◖ ●●
4 Record and display pregnancy and breast-feeding status ●●●◖◖● ◖
5 Record, display and sort current and past medicines (other than complementary medicines) ● ◖◖◖◖◖◖
6 Record and display patient identifying information ◖◖◖◖◖◖◖
7 Record complementary medicines ◖◖◖◖◖◖◖
8 Record medicine changes ◖◖◖◖◖◖◖
9 Record preventive and non-pharmacological management in a specified format ○○○○○○○
Medicine selection
10 Easily select correct problem or diagnosis from a list ●●●●●●●
11 Access to regulator-approved product information ●●●●●●●
12 Provide drug strength and form information ●●●●●●●
13 Provide adult and child dosing information ●●●●●●●
14 Display active ingredient/s when a branded product selected ○ ● ○ ●●○ ●
15 Access to (other) evidence-based drug information at the time of prescribing ● ○ ● ○○○○
16 Access to dose calculators ● ○ ● ○○○○
17 Differentiate between similar name medicines on a list ◖ ● ◖ ○○○○
18 Record indication for medicine prior to prescribing ○○○● ○○○
19 Provide pre-defined dosage regimens for selection ○○○○○○○
Decision support
20 Alerts for drug-drug interactions ●●●●●●●
21 Alerts for drugs in pregnancy ●●●●●●●
22 Alert for same patient name (on opening or creating record) ●●●●●●◖
23 Alerts for drug allergy or intolerance ●●●●◖◖◖
24 Preview and confirm correct patient details prior to electronic transmission of data ◖ ● ◖ ● ◖ ● ◖
25 Alerts for drugs in breastfeeding ●●●○○○○
26 Alerts for therapeutic duplication ●●●○○○○
27 Alerts for drug-condition contraindications ● ◖ ● ○○○○
28 Alerts for drug use in patients with renal impairment ● ○ ● ○○○○
29 Alerts prioritised by importance ○○○● ○ ● ○
30 Access to patient data related to alert ○○○○●●○
31 Alerts for harmful dose, dosage regimen or quantity ◖ ○ ◖ ○○○○
32 Alerts for safety issues related to specific products ○○○○○○○
Patient education and information
33 Provide patient clinical information and tools ● ◖ ● ◖ ● ◖◖
34 Produce current medicine list–patient version ◖ ● ◖◖◖◖◖
35 Provide patient medicine information ◖◖◖◖◖◖◖
Monitoring, reminders and recalls
36 Reminder–action test results ●●●●●●●
37 Reminder–overdue tests ●●●●●●●
38 Displays laboratory results usefully ●●●●●●●
39 Recalls–manually flagged for individual patients ●●●●●●●
40 Produce reports–individual and practice level ●●●●◖ ●●
41 Display medicine information with relevant outcomes ●●●●●○○
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Page 5 of 8varied markedly. For example, in only one system could
we easily produce a report to identify patients who had
not returned for their third dose of human papilloma-
virus vaccine.
￿ Pharmaceutical advertising was present in two sys-
tems. This was displayed at the time of prescribing,
often in a colourful, flashing format. Subsequently both
systems removed this form of advertising.
Discussion
Findings
The seven clinical software systems tested in this study
all included some important safety and quality features
however there were also gaps and limitations, as out-
lined above. The scope and quality of decision support
features were particularly variable–this followed from
differences in the knowledge bases used, or in some
cases differences in the way a knowledge base was
incorporated in the system. Some recommended fea-
tures could not be implemented at the time of the
study, for example because there was no nationally
accepted messaging standard or drug and disease
terminology.
The user interfaces differed substantially from system
to system and many features were implemented in dif-
ferent ways, reflecting in part a lack of guidance for
standardisation of clinical software. Up until recently
there was little information or evidence on how to
design the clinical software interface for usability and
patient safety, however there is now work being done in
this area [8-10].
Many of the software vendors welcomed the feedback
from the study and indicated that they would incorpo-
rate changes to improve their products. Apart from one
company which develops its own in-house drug and
decision support database, the others were reliant on
commercial knowledge bases for decision support and
they had little control over the content. They are keen
for guidance and standards to facilitate development
and interoperability of their products. The study has
raised awareness of these issues in the medical software
industry and has stimulated discussion about software
standards.
Strengths and limitations
The software evaluation process was complex and
resource intensive, and has not been done on this
scale before in Australia. The methods for producing
test scripts and the test process itself were developed
and refined over the course of the project. Limita-
tions of the study include that we did not measure
the usability of features or examine in detail the
quality of the integrated information, thus features
that were fully implemented were present but would
not necessarily perform optimally in practice. A small
number of test examples were used to test each fea-
ture; these were intended to be typical and were not
exhaustive. Lastly, testing was done in a ‘laboratory’
environment using the default system settings; in
real-life practice, these systems may perform differ-
ently depending on the local system configuration
and prescriber behaviour.
Table 1 Implementation of 50 features* in 7 prescribing systems (Continued)
42 Produce reports–predefined ●●●◖ ● ○○
43 Produce reports–user defined ◖◖◖● ◖◖○
44 Recalls and reminders–preventive care and public health programs ◖◖◖● ○○○
45 Reminder–routine or recommended tests ○ ◖ ○○○○○
Interoperability and communication
46 Import/export of a range of file formats ●●●●●◖◖
47 Generate standard patient medicine chart ●●●●●○○
Security and administration
48 System back-up and restore process is straightforward and secure ●●●●●●●
49 System and content updates are reliable and easy to install ●●●●●●●
Transparency
50 Exclude all advertising Advertising was present in 2 systems**
● fully implemented (all test criteria met).
◖ partially implemented (some test criteria met).
○ not implemented (no test criteria met).
Notes
* There were 7 other features that were classified as high impact on safety and/or quality but are not included in this table because they were either (a) tested
but not able to be scored (knowledge base–content quality; use of standard messaging protocol; import/export patient clinical data) or (b) were considered
‘aspirational’ at the time of the study and were not tested (alerts for best practice therapy; use of standard clinical terminologies and coding; support for
selection of therapeutic options; use of a national unique patient identifier).
** Not shown as this would enable identification of these systems.
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Other researchers have also reported limitations in the
safety features and functionality of clinical software sys-
tems. Fernando et al tested prescribing safety features in
four general practice computer systems that were used
by about 75% of GP practices in the UK [11]. The num-
ber of appropriate alerts displayed in the four systems
tested ranged from three to seven, out of a maximum
score of 18. Examples of scenarios tested were “aspirin
prescribed for a child of 8 years”, “methotrexate pre-
scribed in pregnancy” and “sildenafil prescribed to a
patient already using isosorbide mononitrate”. Overall,
problems included a lack of contraindication alerts, the
presence of spurious alerts, failure of drug allergy warn-
ings, ease of overriding most alerts, and lack of audit
trails [12].
Wang et al [13] conducted a field study in the United
States to find out which of 60 recommendations to
improve patient health outcomes and patients’ ability to
manage costs made by Bell et al [14] had been imple-
mented in ten outpatient clinical software systems. For
example, they examined whether systems provided
access to evidence based information on drug effective-
ness and safety at the time of prescribing, and whether
the prescriber was alerted when a medication selected
had a contraindication or precaution based on the
patient’s allergies, current medications, medical condi-
tions or laboratory findings. There was marked variation
between the ten systems tested, with implementation of
the 60 recommendations ranging from 33-77%. There
are similarities between our results and those of both
Fernando et al [11] and Wang et al, [13] notably in the
variable implementation of software features related to
the medicine selection process and clinical decision
support.
General recommendations
Some general recommendations can be made based on
our findings. Clinical decision support should be based
on high quality, evidence based knowledge bases and
appropriate rules; it should be clear and concise, and
should include details about the source and currency of
the information. Messages that disrupt the workflow (eg.
alerts and warnings) should be limited in number to
reduce alert fatigue, and information of lesser clinical
importance should not interrupt the workflow. Clinical
resources should be readily accessible during the consul-
tation, with information available in a format that is easy
to navigate (eg. not large PDF documents). Patient
resources and reports should be presented in a user-
friendly format and use appropriate language.
The system should assist the clinician to maintain up
to date medicines and conditions lists. In order to
reduce selection errors, pick lists (eg. for medicines)
should be limited in length and should be presented so
that it is easy to differentiate between similar items.
Scrolling should be avoided where possible, and espe-
cially in small windows. The query and reporting func-
tion should be flexible and easy to customise by an
average user. The import and export of patient data
between systems would be facilitated by an agreed docu-
ment structure, use of the same (or mapped) medicines
and clinical terminologies, and a defined minimum data-
set for general practice (or other domain).
Need for software standards and certification
Our study shows that current Australian clinical soft-
ware systems include some beneficial decision support
tools and useful resources, but that there are also note-
worthy flaws, such as potential for medicine selection
errors and lack of or poor quality decision support in
some areas. Standards and certification for clinical soft-
ware would ensure that safety features are present and
that there is a minimum level of clinical functionality
that clinicians could expect to find in any system.
There is work underway internationally to define clini-
cal software capabilities in various healthcare settings.
For example in the UK the NHS has defined functional
specifications for secondary care, [15] and data inter-
change standards for primary care [16]. In the US the
Certification Commission for Health Information Tech-
nology (CCHIT) has produced certification criteria for a
range of different types of electronic health record sys-
tems [17]. The feature list from this study could be used
as the basis for development of software standards to
support quality and safety in Australian general practice.
Further work
There is a lot of activity in this area–much is being
learnt and new functionality will become possible as
technologies and systems are developed and software
vendors seek to improve their systems. Any list of
recommended software features or evaluation of soft-
ware systems requires ongoing review.
From a research perspective, some of the features
could be evaluated in more depth, as we have done pre-
viously for drug interaction decision support [18]. It was
evident during the study that more work needs to be
done to develop high quality knowledge bases that pro-
vide content for decision support, and that usability is a
crucial issue that warrants evaluation and development
of guidelines for software developers.
Conclusion
Clinicians are increasingly reliant on their clinical soft-
ware systems. Current systems used by general practi-
tioners in Australia vary widely in their ability to
support quality and safety in relation to prescribing and
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Page 7 of 8use of medicines. The work we have undertaken is an
important precursor to achieving greater standardisation
of clinical software systems.
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